Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

GeNeuro, NINDS ink deal for pHERV-K antibody
December 2018
SHARING OPTIONS:

GENEVA—GeNeuro recently announced the establishment of an exclusive worldwide license with the National Institute of Neurological Disorders and Stroke, part of the U.S. National Institutes of Health, to develop an antibody program to block the activity of pHERV-K Env (pathogenic envelope protein of the HERV-K family of Human Endogenous Retroviruses), which plays a key role in the development of amyotrophic lateral sclerosis (ALS). GeNeuro has initiated a preclinical program for the antibody, and is aiming to have an IND by mid-2020.
 
“GeNeuro’s mission is to leverage its expertise in HERV biology to bring potential new treatments to patients, particularly in areas of high medical needs, such as ALS. We are fortunate and proud to have worked with the NINDS team led by Dr. Avindra Nath to maximize efficiencies and increase the chances of success for this new approach targeting pHERV-K Env,” said Hervé Perron, chief scientific officer at GeNeuro.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.